Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Latest independent research from Spherix Global Insights highlights growing urgency to treat PNH with complement or factor inhibitors, shifting physician preferences, and the impact of biosimilar eculizumab entering the market. [Exton, PA, March 18, 2025] – Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately
Vafseo is currently only approved in dialysis patients with chronic kidney disease-related anemia thanks to safety concerns raised by the FDA. Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia Therapeutics’ endgame remains focused on pushing the therapy into a
In the plaque psoriasis arena, Sotyktu is facing off against Amgen’s Otezla and is facing the threat of upcoming competition from Alumis’ investigational TYK2 inhibitor. Bristol Myers Squibb is building up to a label expansion for Sotyktu, with positive late-stage results from the POETYK PsA-2 study pointing to the potential of its TYK2
Formalizing a longstanding collaboration to unite patient advocacy and market expertise to drive advancements in kidney patient care. EXTON, PA., February 19, 2024 — Spherix Global Insights is proud to announce its partnership with the American Kidney Fund (AKF), marking a significant milestone in a collaboration aimed at advancing kidney
There are signs Bimzelx is affecting the psoriatic arthritis market. UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis (PsA) launch. Yet, the analysis suggests UCB has work to do
Rheumatologists’ perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch mark, according to Spherix Global Insights EXTON, PA, February 13, 2024 – UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis (PsA) market, with early indicators
Analysis of over 1,000 chronic kidney disease patient charts shows GLP-1 receptor agonist use nearly doubling from 2023 to 2024. Exton, PA., February 4, 2025 –– As chronic kidney disease (CKD) management evolves, new findings from Spherix Global Insights’ annual Patient Chart Dynamix™: CKD Non-Dialysis (US) service reveal a sharp
Despite greater physician pre-approval familiarity with Omvoh compared to J&J Innovative Medicine’s Tremfya, gastroenterologists favor Tremfya over Omvoh for Crohn’s disease. Exton, PA., January 29, 2025 – The FDA’s approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor available
Currently, many lupus nephritis treating rheumatologists and nephrologists delay initiating triple therapy, with a significant portion deferring a triple therapy regimen until an initial failure. EXTON, PA., October 8, 2025 – At the 2024 American College of Rheumatology (ACR) Convergence, the organization unveiled updated guidelines for the screening, treatment, and
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights. A top-line data point from the survey suggests that, among patients with SLE currently treated with biologics by the 100 rheumatologist respondents, 62%
Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $220 from $212 and keeps an Overweight rating on the shares. The firm is increasing its Skyrizi and Rinvoq estimates and price target following insights from proprietary survey data with its partners at Spherix, showing meaningful
Spherix Global Insights Announces New Study on Impact of Inflation Reduction Act (IRA) on Specialty Practices and Key Insights for Biopharmaceutical Companies in 2025. Exton, PA., December 10, 2024 – In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various
Spherix Global Insights’ analysis of over 200 PNH patient records reveal current treatment patterns and opportunities for emerging therapies, including Fabhalta (Novartis), Voydeya (AstraZeneca/Alexion), and PiaSky (Genentech/Roche). EXTON, PA., November 21, 2024 — Spherix Global Insights has released its first annual chart audit study in hematology, Patient Chart Dynamix™ : Paroxysmal
Spherix Global Insights notes that differentiation among the IL-23 therapies “will be essential” as Tremfya and Omvoh look to battle class front-runner Skyrizi. (AbbVie) The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly growing into the established UC market as
Findings from Spherix Global Insights show that practitioners consider nearly half of their C3G patients to be potential candidates for Fabhalta or Empaveli, if approved. EXTON, PA, November 15, 2024 — Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G
Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation. Exton, PA., November 15, 2024 – In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson &
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
